Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2709463 | 0.87 | RXRA (0.62) | RXRARXRBRXRGGAAEGLN1 | |
| SCHEMBL181967 | 0.87 | RXRA (0.48) | RXRARXRBRXRGMRGPRX4GAA | |
| SCHEMBL17104926 | 0.85 | KDM4E (0.50) | RXRARXRBKDM4EALDH1A1MEN1 | |
| SCHEMBL181985 | 0.84 | ADH5 (0.51) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL181771 | 0.82 | MRGPRX4 (0.45) | RXRARXRBRXRGMRGPRX4KDM4E | |
| SCHEMBL182269 | 0.79 | RXRA (0.49) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL10195827 | 0.78 | RXRA (0.56) | RXRARXRBMEN1GAAKMT2A | |
| SCHEMBL182330 | 0.77 | TUBB4A (0.48) | RXRARXRBRXRGKDM4EALDH1A1 | |
| SCHEMBL2627836 | 0.77 | RXRA (0.71) | RXRARXRBRXRGMRGPRX4GAA | |
| SCHEMBL16775448 | 0.77 | RXRA (0.52) | RXRARXRBRXRGKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9051342-B2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases | PTC THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051342-B2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases | PTC THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2402323-A2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-2363129-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2316452-A1 | Pyrrol derivatives, uses thereof | PTC Therapeutics, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | RXRA 3985/4885RXRB 3931/4885RXRG 4095/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | RXRA 4114/4885RXRB 4124/4885RXRG 4167/4885 |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, RNMT, VHL | RXRA 3460/4885RXRB 3436/4885RXRG 3529/4885 |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | UPF1, RNMT, VHL | RXRA 3460/4885RXRB 3436/4885RXRG 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.